ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The rapid rise of antimicrobial resistance (AMR), marked by declining efficacy of existing antibiotics against bacterial pathogens, has become a serious global health threat. Increasing resistance in the Staphylococcus aureus pathogen urgently demands the development of effective novel antibacterial agents. In this study, we investigated the previously reported antibacterial beddomeilactone amide (3g) as a potential DNA gyrase inhibitor of S. aureus. The potent hit (3g) exhibited > 90% reduction in DNA supercoiling at an effective concentration of 100 µM. Further, computational studies including molecular docking and dynamics simulation showed that the 3g molecule exhibited a favourable binding affinity of -12.33 kcal/mol, reflecting predicted stable interactions with DNA gyrase. Moreover, Density functional theory (DFT) findings further revealed key electronic properties, frontier molecular orbitals, and chemical reactivity of the compounds. These findings underscore potent hit (3g) as a promising candidate for the development of an antibacterial agent against S. aureus by targeting DNA gyrase.
Indexed as
Identifiers
42517888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.